Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients

Conclusion: The mutation count of tumor-specific mutations can be a monitoring marker of TKI treatment in NSCLC patients.

Source: Cancer Genomics and Proteomics - June 22, 2020 Category: Cancer & Oncology Authors: CHIOU, C.-C., WANG, C.-L., LUO, J.-D., LIU, C.-Y., KO, H.-W., YANG, C.-T. Tags: Article Source Type: research